Patents by Inventor Ina HELLMANN

Ina HELLMANN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • HUMAN ANTIBODIES BINDING TO ROR2
    Publication number: 20220372143
    Abstract: The present invention relates to fully human antibodies and conjugates thereof, which specifically bind to the extracellular domain of receptor tyrosine kinase-like orphan receptor 2 (ROR2).
    Type: Application
    Filed: July 22, 2022
    Publication date: November 24, 2022
    Inventors: Ulf GRAWUNDER, Roger BEERLI, Ina HELLMANN, Lorenz WALDMEIER
  • Human antibodies binding to ROR2
    Patent number: 11447546
    Abstract: The present invention relates to fully human antibodies and conjugates thereof, which specifically bind to the extracellular domain of receptor tyrosine kinase-like orphan receptor 2 (ROR2).
    Type: Grant
    Filed: July 20, 2018
    Date of Patent: September 20, 2022
    Assignee: NBE-THERAPEUTICS AG
    Inventors: Ulf Grawunder, Roger Beerli, Ina Hellmann, Lorenz Waldmeier
  • HUMAN ANTIBODIES BINDING TO ROR2
    Publication number: 20200354449
    Abstract: The present invention relates to fully human antibodies and conjugates thereof, which specifically bind to the extracellular domain of receptor tyrosine kinase-like orphan receptor 2 (ROR2).
    Type: Application
    Filed: July 20, 2018
    Publication date: November 12, 2020
    Inventors: Ulf Grawunder, Roger Beerli, Ina Hellmann, Lorenz Waldmeier
  • ANTI-MESOTHELIN ANTIBODIES
    Publication number: 20190112385
    Abstract: The present invention relates to a human or humanized antibody, or an antibody-based binding protein, modified antibody format retaining target binding capacity, antibody derivative or fragment retaining target binding capacity, which targets Mesothelin (MN). It further relates to bi- or multispecific antibodies, to Immunoligand-Drug Conjugates, to Chimeric Antigen Receptors and to T-cells comprising such Chimeric Antigen Receptors.
    Type: Application
    Filed: October 31, 2016
    Publication date: April 18, 2019
    Applicant: NBE-THERAPEUTICS AG
    Inventors: Ina HELLMANN, Lorenz WALDMEIER, Ulf GRAWUNDER, Roger BEERLI